Market: NASD |
Currency: USD
Address: Perryville III Building
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.
📈 Celldex Therapeutics, Inc. Historical Chart
📊 Statistics
-
Analyst 1 Year Price Target:
$55.62
-
Upside/Downside from Analyst Target:
155.70%
-
Broker Call:
26
-
Dividend Minimum 3 Year Yield:
0.00%
-
EPS Growth Range (1Y):
<0%
-
Net Income Growth Range (1Y):
<0%
-
Revenue Growth Range (1Y):
<0%
-
Upcoming Earnings Date:
2025-11-06
-
EPS Estimate:
-0.89
💰 Dividend History
| Year |
Annual Yield (%) |
Total Amount |
Current Yield (%) |
Ex Date |
Pay Date |
Particulars |
| 2019 |
- |
$0.066667 |
- |
2019-02-11 |
- |
Stock split |
|
Total Amount for 2019: $0.066667 |
📅 Earnings & EPS History for Celldex Therapeutics, Inc.
| Date | Reported EPS |
|---|
| 2025-11-05 (estimated upcoming) | - |
| 2025-08-07 | -0.85 |
| 2025-05-08 | -0.81 |
| 2025-02-27 | -0.71 |
| 2024-11-06 | -0.64 |
| 2024-08-08 | -0.54 |
| 2024-05-06 | -0.56 |
| 2024-02-26 | -0.59 |
| 2023-11-02 | -0.81 |
| 2023-08-08 | -0.65 |
| 2023-05-04 | -0.62 |
| 2023-02-28 | -0.56 |
| 2022-11-09 | -0.57 |
| 2022-08-08 | -0.58 |
| 2022-05-05 | -0.5 |
| 2022-02-28 | -0.46 |
| 2021-11-09 | -0.37 |
| 2021-08-05 | -0.34 |
| 2021-05-06 | -0.42 |
| 2021-03-29 | -0.2 |
| 2020-11-05 | -0.36 |
| 2020-08-06 | -0.57 |
| 2020-05-06 | -0.73 |
| 2020-03-26 | -0.62 |
| 2019-11-12 | -0.75 |
📰 Related News & Research
No related articles found for "celldex therapeutics".
